Abstract
Introduction
The transcription factor p73 is a multifunctional protein, able to induce cell cycle arrest, apoptosis and differentiation [1] [2] [3] . The P73 gene gives rise to a vast number of isoforms due to alternative splicing and use of alternative promoters. Isoforms generated by the two promoters are called TA (for transactivation) and ⌬N, the latter lacking the amino-terminal TA domain [4] .
In addition, alternative splicing generates at least seven transcripts with different carboxy-terminals (␣ -). However, TAp73␣ and TAp73␤ are the two main p73 isoforms expressed in human cells. TAp73␣ possess the longest carboxy-terminal extension and is the only TAp73 isoform to contain a sterile ␣ motif (SAM) domain. TAp73␤ is shorter and lacks the extreme carboxy-terminal and SAM
domain found in TAp73␣ [1, 5] . The ⌬Np73 isoforms are regarded as potential oncogenes, capable of counteracting the effects of TAp73 isoforms and p53 [6] . In contrast to the P53 gene, frequently mutated or deleted in cancer, the P73 gene is very rarely found mutated in tumours. Instead, expression of p73 is greater in a range of tumours compared with normal tissues [7, 8] .
Particularly an increased expression of the TAp73␣ isoform has been reported in medulloblastoma [9] , B-cell chronic lymphocytic leukaemia [10] , ovarian carcinomas [11] , gastric adenocarcinoma [12] , bladder cancer [13] and thyroid cancer [14] . Moreover, TAp73␣ was found to promote tumour resistance in response to treatment with DNA-damaging agents in an ovarian cancer cell line [15] . In line with these data, we previously reported that TAp73␣ inhibits drug-induced apoptosis in small cell lung carcinoma (SCLC) cells. The anti-apoptotic effect is exerted upstream of the mitochondria, at the level of Bax activation [16] . Interestingly, a protein known to inhibit Bax activation is the inducible heat shock protein HSPA1A/Hsp72/Hsp70-1 (referred to later as Hsp72) [17] . Hsp72 has also been shown to stabilize lysosomal membranes [18] and prevent other apoptotic events such as loss of mitochondrial membrane potential (⌬⌿m) [19] , and subsequent release of proapoptotic mitochondrial proteins [19] , formation of the apoptosome complex [19] [20] [21] , and caspase activation [19, 22] . ⌬Np73␣ can via the activation of heat shock factor-1 (HSF-1) cause upregulation of HSF-responsive genes, one major target gene being HSPA1A/HSP72 (referred to later as HSP72) [23] . This 
Plasmids and small interfering RNAs
Expression vectors encoding human p73 isoforms (TAp73␣, TAp73␤, ⌬Np73␣) were gifts from Dr. G. Melino and have been described [24] 
RNA isolation and PCR analysis

-GGA GCC CCC ACC TAC TCG CT-3Ј), G3PDH (forward primer 5Ј-ATG GCC TTC CGT GTC CCC ACT G-3Ј and reverse primer 5Ј-TGA GTG TGG CAG GGA CTC CCC A-3Ј).
Statistical analysis
Statistical analyses were performed with two-tailed, paired Student's t-test, where ***P Ͻ 0.001, **P Ͻ 0.01 and *P Ͻ 0.05.
Results
TAp73␣ induces Hsp72 expression
We have shown that full-length TAp73␣ represses drug-induced apoptosis in SCLC cells, whereas full-length TAp73␤ strengthens drug-induced apoptosis in the same settings [16] . In addition, the anti-apoptotic actions of TAp73␣ upon drug-induced apoptosis was shown to be exerted upstream of the mitochondria, on the level of Bax [16] . Previously, the capability of the ⌬N forms of p73 and p63 (⌬Np73␣ and ⌬Np63␣) to regulate the expression of Hsp72 has been demonstrated [23, 28] . Moreover, similar to TAp73␣, Hsp72 has been shown to exert many of its pro-survival functions upstream of the mitochondria [17] (Fig. 1C) and by immunoblot on HEK-293 cell extracts (Fig. 1D) . However, no effect of either TAp73␣ or TAp73␤ expression could be detected on the levels of the Hsp72-related proteins HSF1, Hsp90/HSPC1, Hsc70/HSPA8 or Hsp27/HSPB1 (Fig. 1E) . As control, Hsp72 protein expression during VP16 treatment and up to 24 hrs is also depicted in Figure S1A . Thus, based on these data we conclude that TAp73␣ is a selective and potent inducer of Hsp72 expression. (Fig. 2D , and as previously reported [16] ). Upon co-transfection of ⌬Np73␣ with asHsp72, ⌬Np73␣ still exhibits an anti-apoptotic effect upon VP16 treatment (Fig. 2D, ⌬Np73␣ black and grey bars) . These data were further confirmed using a siRNA targeting HSP72/HSPA1A mRNA ( Fig. 2E and F) . This indicates the anti-apoptotic effect of ⌬Np73␣ being independent on induction of Hsp72, consistent with the data described above (Fig. 1 Fig. 3A) and confocal imaging (Fig. 3B) (Fig. 5C ) and FACS analysis (Fig. 5D) . Hence, TAp73␤-mediated Bax activation and disruption of ⌬⌿m in response to VP16 can be prevented by the simultaneous expression of Hsp72. 
) where, in H82 cells, ⌬Np73␣ do not show any induction of Hsp72, neither on the level of the promoter nor on mRNA and protein levels. The pro-apoptotic activity of TAp73␤ was unaffected by the co-expression of asHsp72. However, cotransfection of TAp73␣ together with asHsp72 significantly reduced the anti-apoptotic effect of TAp73␣ (Fig. 2D, TAp73␣ black and grey bars). Hence, the anti-apoptotic activity of TAp73␣ in SCLC H82 cells treated with chemotherapeutic drugs seems to depend on the induction of Hsp72.
Hsp72 represses TAp73␤ pro-apoptotic effect
Given that TAp73␣ is able to induce Hsp72 expression and that the anti-apoptotic activity of TAp73␣ seems to be dependent on this induction, and since it is known from before that the p73 isoforms can interact and regulate the activity of each other [16, 29], we sought to investigate whether the overexpression of Hsp72 could counteract the pro-apoptotic function of TAp73␤ upon druginduced apoptosis. Transfection of H82 cells with Hsp72 vector lead to an enhanced expression of Hsp72 protein, as shown by immunoblot (
TAp73␣ repress Etoposide-induced loss of lysosomal membrane potential in a Hsp72-dependent manner
Etoposide was shown to induce destabilization of lysosomes [18] , an event which in turn can trigger Bax activation in a cathepsin B dependent manner [31] . On the other hand, lysosomal permeabilization has been shown to depend on Bax [32, 33] . Both ways, the destabilization of and subsequent leakage from lysosomal compartments can be prevented by simultaneous co-expression of Hsp72 [34] . Significant LMP in H82 cells upon VP16 treatment is observed by FACS analysis at 24 hrs after exposure (Fig. S1C) [35] . A decreased LysoTracker fluorescence may then reflect LMP and/or an increase in lysosomal pH, which then would lead to less cytosolic puncta [35] , as seen using fluorescence microscopy (Fig. 6C, 
Loss of ⌬⌿m was assayed by scoring of EGFP transfected cells without TMRE staining using microscopy (A) and FACS analysis (B). (C) H82 cells were transfected and treated as described (A). Samples were stained with anti-active Bax antibody (red) and nuclei counterstained with Hoechst (blue). (D) Cells were transfected and treated as in (A), stained with anti-active Bax antibody and analysed by FACS.
The Hsp72-mediated anti-apoptotic effect of TAp73␣ can be counteracted by TAp73␤
It is known since before that the p73 isoforms can interact and regulate the activity of each other [16, 29] . Given that TAp73␣ is able to transactivate the HSP72 promoter (Fig. 1 Figure 4A and B, and analysis was carried out using microscopy (A) Figure 4C and [7, 36, 37] . TAp73␤ has been shown a potent transactivator of the Aquaporin 3 [38] and P57 Kip2 [39] [18] and preventing loss of mitochondrial membrane potential [19] , release of pro-apoptotic mitochondrial proteins, apoptosome formation [19] [20] [21] , caspase activation [19, 22] activation [31] , or to be dependent on active Bax [32, 33] . However, in SCLC cells Bax activation seems to occur prior to LMP (Fig. S1B and C [45] [46] [47] . Also, an elevated expression of Hsp72 has been reported in tumour cell lines [48] [49] [50] and in several tumour cases [51] . Interestingly, selective down-regulation of Hsp72 by small interfering RNA's or antisense constructs promotes drug-induced cell death in a range of different tumour cell lines, e.g. cervical carcinoma (HeLa) [52] , colon carcinoma, hepatocellular carcinoma [53] and breast cancer [49] . Hence, the possibility of a tumour cell to induce expression of Hsp72 seems to provide it with an advantage towards drug-induced cell death.
and FACS analysis (B). (C, D) H82 cells were transfected, treated and stained as described in
Consequently, with these data we reinforce the idea that there is indeed a balance between the two main TAp73 isoforms, TAp73␣ and TAp73␤. We have previously shown that TAp73␣ can counteract the pro-apoptotic effect of TAp73␤, and vice versa [16] . Here 
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